Versuchen GOLD - Frei

AIC chief seeks review of PMFBY

Business Standard

|

July 10, 2025

With the Narendra Modi government's flagship crop insurance scheme, the Pradhan Mantri Fasal Bima Yojana (PMFBY), nearing a decade since launch, Lavanya R Mundayur, chairman and managing director of the Agriculture Insurance Company (AIC) of India, spoke with Harsh Kumar and Sanjeeb Mukherjee in New Delhi. She shared her views on the scheme's performance, lessons learnt, and where course correction was needed. She also discussed AIC's road map and plans for business expansion.

AIC chief seeks review of PMFBY

PMFBY is a major part of your business. Where do you see it heading now?

PMFBY continues to make up a considerable portion of our portfolio. The number of farmers covered is steadily increasing, and participation by non-loanee farmers is also growing. However, the overall business remains somewhat flat.

What is the subscription cost, and how are premiums trending?

Premium rates are decreasing, thanks to the caps introduced in most states. Today, you'll see models like 81:10 or 61:30 in most places. The fully open premium model is almost non-existent now. States are experimenting with structures like burn-cost models, but the pricing framework remains dynamic.

If the product is so good, why isn't coverage expanding beyond this?

That's the core issue. We're now almost a decade into the scheme, but coverage—in terms of both farmers and area—has plateaued. While the active crop cultivation base is about 80 million farmers, the number covered under PMFBY should be much higher.

Where is the resistance or challenge coming from?

I wouldn't call it resistance; it's more about the complexities of the ecosystem. We are dependent on banks and other intermediaries. Crop insurance is a sensitive business, with moving parts.

Do you think making the scheme voluntary was a mistake?

WEITERE GESCHICHTEN VON Business Standard

Business Standard

Labour Codes impact: HCL tech profit slips 11%

Q3 top line beats Street estimates, bottom line misses expectations

time to read

2 mins

January 13, 2026

Business Standard

New labour Codes, restructuring weigh on TCS earnings

Tata Consultancy Services (TCS), India’s largest information technology (IT) services firm, saw its profit impacted in the October-December quarter by restructuring and changes in labour Codes.

time to read

1 min

January 13, 2026

Business Standard

Business Standard

Black drives the thrill for car buyers

Sees a surge in yearly sales, while white remains practical 'utility king'

time to read

2 mins

January 13, 2026

Business Standard

CHOOSING THE RIGHT B-SCHOOL TO MATCH YOUR CAREER GOALS

Success comes when you pick an institution that fits your professional dreams and your personality, helping you become the leader you want to be

time to read

2 mins

January 13, 2026

Business Standard

Business Standard

China’s PVC rethink to help India pipe makers

Supply likely to tighten after S-PVC rebate withdrawal

time to read

2 mins

January 13, 2026

Business Standard

Responsible growth

India must ensure data centres are sustainable

time to read

2 mins

January 13, 2026

Business Standard

India’s GenZ is full of creativity: PM

Prime Minister Narendra Modi on Monday said India's GenZ is full of creativity and with innovative ideas, energy and purpose, the country’s youth is at the forefront of nation-building.

time to read

1 min

January 13, 2026

Business Standard

Business Standard

Iran wants to negotiate after threats to attack, says Trump

At least 572 killed in protests; Tehran says situation ‘under full control’

time to read

2 mins

January 13, 2026

Business Standard

Insurers knock on Irdai door for clarity on director overlap ban

CLAUSE THREATENS BOARD STRUCTURES AT BANK-BACKED FIRMS SAYS INDUSTRY

time to read

2 mins

January 13, 2026

Business Standard

Delhi HC allows Zydus to sell generic version of cancer drug

Citing public interest, the Delhi High Court has cleared the way for Zydus Life-sciences to proceed with the sale of its version of the cancer drug nivolumab in India.

time to read

1 min

January 13, 2026

Listen

Translate

Share

-
+

Change font size